Long-Term Culture System for Selective Growth of Human B-Cell Progenitors (Cord Blood/Gene Expression/Interleukin 7/Stem Cell Factor/Murine Stroma) DAVID J

Total Page:16

File Type:pdf, Size:1020Kb

Long-Term Culture System for Selective Growth of Human B-Cell Progenitors (Cord Blood/Gene Expression/Interleukin 7/Stem Cell Factor/Murine Stroma) DAVID J Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1570-1574, February 1995 Immunology Long-term culture system for selective growth of human B-cell progenitors (cord blood/gene expression/interleukin 7/stem cell factor/murine stroma) DAVID J. RAWLINGS*, SHIRLEY G. QuANt, ROBERTA M. KATO*, AND OWEN N. WiTrE* *Department of Microbiology and Molecular Genetics, and tHoward Hughes Medical Institute, University of California, 5-748 MacDonald Research Laboratory, 10833 Le Conte Avenue, Los Angeles, CA 90024-1662 Communicated by Max D. Cooper, University ofAlabama, Birmingham, AL, October 21, 1994 ABSTRACT We describe a simple reproducible system for Establishment and maintenance of murine long-term cultures enrichment and long-term culture of human B-cell progeni- is dependent upon an adherent stromal cell microenvironment tors. Enriched CD34- cord blood mononudear cells are (4-6). Cultured cells develop and proliferate in direct association seeded onto a murine stromal cell line to establish a biphasic with stromal cells. While growth factors including interleukin 7 culture system. These cultures are characterized by transient (IL-7) and stem cell factor (SCF) are important for early B-cell growth of myeloid cells followed by outgrowth of cells highly lineage expansion, additional as-yet-unidentified stromal factors enriched for early B-cell progenitors. Cultures consisting of probably play a critical role in these processes (4, 5). Human >90%o early B-lineage cells [expressing CD10, CD19, CD38, B-lymphopoiesis is also likely to require close association with a and CD45 but lacking CD20, CD22, CD23, and surface IgM] stromal microenvironment. Human bone marrow stromal cells are maintained for > 12 weeks without growth factor addition. have been used to support short-term growth and proliferation of Cells remain predominantly germ line at the immunoglobulin CD10+, sIgM- human B-lineage cells (12, 14-16, 19). Establish- locus and express only low levels of cytoplasmic ,u chain, ment of long-term B-lymphoid cultures using human stroma has terminal deoxynucleotidyltransferase, and recombination- been limited in part by the need to repeatedly establish primary activating gene 1 product. They are unresponsive to the pre- stromal cultures and problems associated with transformed lines B-cell growth factors interleukin 7 or stem cell factor, or both, (20, 21). suggesting that growth support is provided by a cross-reactive Recently, several murine stromal lines have allowed support murine stromal cell factor. Cultured B-cell progenitors are of human hematopoietic progenitor cells in long-term cultures generated in large numbers (>108 cells from a typical cord and colony assays (22-24). Most notably, Baum et al. (24) blood specimen) suitable for use in biochemical analysis and established long-term cultures of Thy-1+, CD34+ cells on gene-transfer studies. This system should be useful for study murine stroma without additional growth factors. Those cells of normal and abnormal early human B-lymphopoiesis. remain capable of both myeloid and B-cell engraftment of in- tact human bone marrow implanted in severe combined im- Antigen-independent early B-cell development (B-lymphopoi- munodeficient (SCID) mice. In this paper we describe adap- esis) is characterized by an orderly expression of regulatory tation of these observations and conditions previously devel- genes, surface molecules, and gene rearrangements leading to oped for culture of murine B-cell progenitors to establish a the generation of surface IgM+ (sIgM+), sIgD+ mature B cells. long-term culture system for selective growth of human B-cell This process is controlled through cell-cell interactions and progenitors. soluble or cell-associated hematopoietic growth factors (1-3). B-lymphopoiesis occurs first in the fetal liver and bone marrow and continues after birth only in the bone marrow. The com- METHODS plexity of mammalian bone marrow precludes detailed in vivo Cord Blood Enrichment for CD34+ Cells, Culture Condi- analysis of these developmental events and has been signifi- tions, and Flow Cytometry. Heparinized (10 units/ml) cord cantly advanced through the establishment of long term B- blood was obtained from umbilical and placental tissues sched- lymphoid culture systems (4-10). Murine lymphoid progenitor uled to be discarded and stored up to 24 hr at room temper- cultures maintain murine immunoglobulin-locus-unrear- ature. Low-density mononuclear cells were collected by Ficoll/ ranged pro-B-cells that undergo limited differentiation. Mu- Hypaque separation (Pharmacia), and enrichment of CD34+ rine long-term bone marrow cultures support growth and cells was performed with a Celprate LC34 Biotin cell separa- spontaneous maturation of pre-B-cells into sIgM+ cells. How- tion column (CellPro, Bothell, WA) as recommended by the ever, cultured cells from both systems can fully reconstitute manufacturer. Briefly, cord mononuclear cells were stained B-cell function in immunodeficient animals (8, 9, 11). with anti-CD34 biotin-conjugated antibody and passed Several culture models have been useful in phenotypic and through an avidin column. Collected absorbed cells were 40- molecular analysis and in defining the growth factor require- 80% CD34+ by flow cytometry and represented approximately ments of early human B-cell progenitors (12-19). In these 0.5-1% of input cells. Sixty percent confluent S17 stromal cell systems, cultured B-cell progenitors survive for relatively short monolayers (25) were established 1-2 days prior to addition of periods (<4 weeks), and cell expansion is limited (usually CD34+ cord mononuclear cells by plating 2.5 x 105 S17 cells <10-fold). Isolation of highly purified human bone marrow per 10-cm2 tissue culture dish (Falcon). CD34+-enriched cells stem or B-cell progenitor populations and use of growth were plated at a density of 0.5-1 x 105 cells per ml onto the factors has been required to maintain optimal cell growth and S17-coated dishes (10 ml) in RPMI 1640 medium (Irvine expansion. Studies of early human B-lymphopoiesis would be Sciences) supplemented with 3% (vol/vol) defined fetal calf significantly advanced by the development of long-term cul- serum (HyClone) and 50 ,uM 2-mercaptoethanol and 200 mM ture models similar to those available using murine cells. Abbreviations: SCF, stem cell factor; IL-2 and IL-7, interleukins 2 and The publication costs of this article were defrayed in part by page charge 7; sIgM, etc., surface IgM, etc.; RAG1, recombination-activating gene payment. This article must therefore be hereby marked "advertisement" in 1; TdT, terminal deoxynucleotidyltransferase; C, constant region. accordance with 18 U.S.C. §1734 solely to indicate this fact. tTo whom reprint requests should be addressed. 1570 Downloaded by guest on September 30, 2021 Immunology: Rawlings et aL Proc. NatL Acad Sci USA 92 (1995) 1571 glutamine. Single-cell suspensions of cultured cells were incu- then mononuclear cells were enriched for CD34+ progenitor bated on ice for 30 min in saturating amounts of human- cells by using a CD34+ biotin avidin column. This enrichment specific monoclonal antibodies (Becton Dickinson, Southern step resulted in a mononuclear cell population containing Biotechnology Associates) in phosphate-buffered saline with between 50% and 80% CD34+ cells (average, =60% in four 2% calf serum, washed, and fixed in 1% paraformaldehyde. analyses), and further lineage depletion or CD34+ cell enrich- Samples were simultaneously analyzed by using isotype con- ment was not performed. Finally, CD34+-enriched cells were trols. Two-color flow cytometry was performed in a FACScan transferred onto 12-well or 10-cm2 tissue culture dishes con- and analyzed using Lysis II software (Becton Dickinson). The taining a subconfluent monolayer of the murine bone marrow fluorokine human IL-7-conjugated biotin and SCF-conjugated stromal cell line S17. The S17 stromal cell line was chosen biotin (R & D Systems) were used to detect IL-7 and SCF because of its ability to maintain long-term murine pro-B-cell receptors. Immunofluorescent terminal deoxynucleotidyl- growth (9, 10, 25, 30, 31). A seeding density of 0.1-5 x 105 cells transferase (TdT) staining (Supertechs, Bethesda, MD) was per ml resulted in the most consistent establishment of cul- performed on cytospin preparations. tures. Attempts to establish cultures by using unfractionated or Nucleic Acid Analysis. High molecular weight DNA and adherence-depleted cord mononuclear cells were unsuccess- total RNA were prepared and analyzed by standard methods. ful. For analyses, cultured cells were harvested with the ad- The human JH DNA probe (Oncogene Science) and other herent-cell monolayer by vigorous pipetting ahd passage probes were labeled by random primer DNA labeling (Primelt, through a needle and or cell sieve (40 ,um) to eliminate cell Stratagene) and had specific activities of 109 cpm/,ug of clumps. S17 cells could be easily distinguished from long-term DNA. cultured cells. Cytokines and Growth Factor Stimulation. Recombinant Establishment of long-term cultures followed three rela- human SCF was provided by K Zsebo and I. McNiece (Am- tively distinct phases: (i) acellular period-during weeks 1-2, gen). Recombinant human IL-7 and anti-IL-7 monoclonal cultures contained only small numbers of nonadherent cells antibody were purchased from Collaborative Biomedical and and significant cell death was observed; (ii) myeloid expan- Genzyme, respectively. For [3H]thymidine incorporation as- sion-during weeks 2-3, there was a marked increase in cel- says, 105 cultured cells per well were grown in medium de- lularity (up to 5 x 105 cells per ml) consisting primarily of scribed above or in S17-conditioned medium in the presence nonadherent myeloid cells identified by Wright stain and flow of growth factor for 48 hr and then were pulsed with 0.5 ,uCi cytometry; and (iii) outgrowth of B-cell progenitors- (1 ,uCi = 37 kBq) of [3H]thymidine for 18 hr before scintilla- beginning at 3-4 weeks, there was a decline in nonadherent tion counting with a multiwell harvester. (myeloid) cells and progressive outgrowth of small round cells tightly adherent to and burrowed within the stroma.
Recommended publications
  • Expression of the Hematopoietic Stem Cell Antigen CD34 on Blood and Bone Marrow Monoclonal Plasma Cells from Patients with Multiple Myeloma
    Bone Marrow Transplantation, (1997) 19, 553–556 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma T Kimlinger1 and TE Witzig2 1Department of Laboratory Medicine and 2Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA Summary: led to strategies to deplete the tumor cells from the harvest product prior to reinfusion of the stem cells. Monoclonal plasma cells (CD38+CD45−/dim) are typi- One of the current attempts at purifying the harvest pro- cally present in the blood of patients with active mye- duct uses antibody to the CD34 antigen to positively select loma and can contaminate stem cell harvests. This has and enrich hematopoietic stem cells and in the process led to strategies that select CD34+ cells for use in auto- purge the stem cell product of tumor cells and T cells.11–13 logous stem cell transplantation with the goal of The CD34 antigen identifies a lymphohematopoietic stem decreasing tumor cell contamination. The aim of this cell, is present on 1–5% of adult bone marrow cells, and study was to learn if the CD34 antigen is expressed on is expressed on early B cells. The characteristics of this monoclonal plasma cells in the blood or marrow of important antigen and its clinical relevance have recently patients with multiple myeloma. We used three-color been reviewed.14 CD34+ hematopoietic cells from blood or flow cytometry (surface CD38;CD45 and cytoplasmic marrow can reconstitute hematopoiesis after high-dose kappa or lambda) to identify monoclonal plasma cells therapy programs.15 The number of CD34+ cells reinfused in the blood (n = 24) and marrow (n = 37) from patients predicts the time to engraftment.16,17 with plasma cell proliferative disorders.
    [Show full text]
  • MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
    Published OnlineFirst July 18, 2013; DOI: 10.1158/0008-5472.CAN-13-0677 Cancer Tumor and Stem Cell Biology Research MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells Dina Stroopinsky1, Jacalyn Rosenblatt1, Keisuke Ito1, Heidi Mills1, Li Yin2, Hasan Rajabi2, Baldev Vasir2, Turner Kufe1, Katarina Luptakova1, Jon Arnason1, Caterina Nardella1, James D. Levine1, Robin M. Joyce1, Ilene Galinsky2, Yoram Reiter3, Richard M. Stone2, Pier Paolo Pandolfi1, Donald Kufe2, and David Avigan1 Abstract Acute myeloid leukemia (AML) is a malignancy of stem cells with an unlimited capacity for self-renewal. MUC1 is a secreted, oncogenic mucin that is expressed aberrantly in AML blasts, but its potential uses to target AML þ À stem cells have not been explored. Here, we report that MUC1 is highly expressed on AML CD34 /lineage / À CD38 cells as compared with their normal stem cell counterparts. MUC1 expression was not restricted to AML þ À CD34 populations as similar results were obtained with leukemic cells from patients with CD34 disease. Engraftment of AML stem cell populations that highly express MUC1 (MUC1high) led to development of leukemia in NOD-SCID IL2Rgammanull (NSG) immunodeficient mice. In contrast, MUC1low cell populations established normal hematopoiesis in the NSG model. Functional blockade of the oncogenic MUC1-C subunit with the peptide inhibitor GO-203 depleted established AML in vivo, but did not affect engraftment of normal hematopoietic cells. Our results establish that MUC1 is highly expressed in AML stem cells and they define the MUC1-C subunit as a valid target for their therapeutic eradication.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Review Article TheScientificWorldJOURNAL (2011) 11, 2011–2019 ISSN 1537-744X; doi:10.1100/2011/671453 The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis Irene Mavroudi1, 2 and Helen A. Papadaki1 1Department of Hematology, University of Crete School of Medicine, P.O. Box 1352, 71110 Heraklion, Crete, Greece 2Graduate Program “Molecular Basis of Human Disease”, University of Crete School of Medicine, 71003 Heraklion, Greece Received 29 August 2011; Accepted 5 October 2011 Academic Editor: Marco Antonio Cassatella The CD40 ligand (CD40L) and CD40 are two molecules belonging to the TNF/TNF receptor super- family, and their role in adaptive immune system has widely been explored. However, the wide range of expression of these molecules on hematopoietic as well as nonhematopoietic cells has revealed multiple functions of the CD40/CD40L interactions on different cell types and processes such as granulopoiesis. CD40 triggering on stromal cells has been documented to enhance the expression of granulopoiesis growth factors such as granulocyte-colony-stimulating factor (G- CSF) and granulocyte/monocyte-colony-stimulating factor (GM-CSF), and upon disruption of the CD40/CD40L-signaling pathway, as in the case of X-linked hyperimmunoglobulin M (IgM) syn- drome (XHIGM), it can lead to neutropenia. In chronic idiopathic neutropenia (CIN) of adults, however, under the influence of an inflammatory microenvironment, CD40L plays a role in granu- locytic progenitor cell depletion, providing thus a pathogenetic cause of CIN. KEYWORDS: CD40L, CD40, granulopoiesis, G-CSF, GM-CSF, Flt3-L, neutropenia, apoptosis, tumor necrosis factor family, and granulocytic progenitor cells Correspondence should be addressed to Helen A.
    [Show full text]
  • Precursors in Human Bone Marrow Identifies Autonomously
    A Feeder-Free Differentiation System Identifies Autonomously Proliferating B Cell Precursors in Human Bone Marrow This information is current as Helene Kraus, Sandra Kaiser, Konrad Aumann, Peter of September 30, 2021. Bönelt, Ulrich Salzer, Dietmar Vestweber, Miriam Erlacher, Mirjam Kunze, Meike Burger, Kathrin Pieper, Heiko Sic, Antonius Rolink, Hermann Eibel and Marta Rizzi J Immunol 2014; 192:1044-1054; Prepublished online 30 December 2013; Downloaded from doi: 10.4049/jimmunol.1301815 http://www.jimmunol.org/content/192/3/1044 Supplementary http://www.jimmunol.org/content/suppl/2013/12/30/jimmunol.130181 http://www.jimmunol.org/ Material 5.DCSupplemental References This article cites 55 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/192/3/1044.full#ref-list-1 Why The JI? Submit online. by guest on September 30, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
    [Show full text]
  • Cell Activation Subsets of Human Dendritic Cells Tunes NK
    Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation This information is current as Barbara Morandi, Roberta Costa, Michela Falco, Silvia of September 29, 2021. Parolini, Andrea De Maria, Giovanni Ratto, Maria Cristina Mingari, Giovanni Melioli, Alessandro Moretta and Guido Ferlazzo J Immunol 2005; 175:3690-3697; ; doi: 10.4049/jimmunol.175.6.3690 Downloaded from http://www.jimmunol.org/content/175/6/3690 References This article cites 46 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/175/6/3690.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation1 Barbara Morandi,* Roberta Costa,† Michela Falco,‡ Silvia Parolini,§ Andrea De Maria,¶ Giovanni Ratto,ʈ Maria Cristina Mingari,*¶ Giovanni Melioli,‡ Alessandro Moretta,¶# and Guido Ferlazzo*2** CD48 is a glycosyl phosphatidylinositol anchor protein known to be virtually expressed by all human leukocytes.
    [Show full text]
  • And Tumor Cells in Kaposi's Sarcoma
    Americani Joirnal ofPathology, Vol. 148, No. 5, May 1996 Copyfight X) American Societyfor Investigative Pathology CD40 Antigen Is Expressed by Endothelial Cells and Tumor Cells in Kaposi's Sarcoma Johannes Pammer,* Andreas Plettenberg,t of CD40 by Kaposi sarcoma tumor ceUs might Wolfgang Weninger,t Barbara Diller,t play an important role in thepathogenesis ofthis Michael Mildner,t Aumaid Uthman,t neoplasm. (AmJPathol 1996, 148:1387-1396) Wolfgang lssing,$ Michael Sturzl,§ and Erwin Tschachlert From the Division ofImmunology,t Allergy, and Infectious The CD40 antigen is a 45- to 50-kd transmembrane Diseases, Department ofDermatology, and Institute of glycoprotein that belongs to the nerve growth factor Clinical Pathology,* University of Vienna Medical School, receptor (NGFR)/tumor necrosis factor receptor Vienna, Austria, and the Department of Otolaryngology,t (TNFR)-superfamily.1 2 Members of this superfamily Grosshadern Clinic, Ludwig Maximilians University, are intimately involved in the regulation of cell sur- Munich, and the Max Planck Institute ofBiochemistry,j vival and include the T cell activation antigen CD27, Martinsnied, Germany the lymphocyte activation antigen CD30, the low af- finity NGFR, the FAS antigen CD95, the TNFRs CD12012 and the lymphotoxin-f3 receptor.3 CD40 was initially described on B cells and certain carci- The CD40 antigen is a member of the tumor ne- nomas.4'5 It has since become clear that it is also crosis factor receptor/nerve growth factor re- expressed on dendritic cells,6 monocytes,7 thymus ceptor superfamily
    [Show full text]
  • Extracellular Matrix and Α5β1 Integrin Signaling Control the Maintenance
    www.nature.com/scientificreports OPEN Extracellular matrix and α5β1 integrin signaling control the maintenance of bone formation Received: 05 December 2016 Accepted: 07 February 2017 capacity by human adipose-derived Published: 14 March 2017 stromal cells Nunzia Di Maggio1,*, Elisa Martella2,3,*, Agne Frismantiene4, Therese J. Resink4, Simone Schreiner1, Enrico Lucarelli2,3, Claude Jaquiery5, Dirk J. Schaefer6, Ivan Martin1 & Arnaud Scherberich1 Stromal vascular fraction (SVF) cells of human adipose tissue have the capacity to generate osteogenic grafts with intrinsic vasculogenic properties. However, adipose-derived stromal/stem cells (ASC), even after minimal monolayer expansion, display poor osteogenic capacity in vivo. We investigated whether ASC bone-forming capacity may be maintained by culture within a self-produced extracellular matrix (ECM) that recapitulates the native environment. SVF cells expanded without passaging up to 28 days (Unpass-ASC) deposited a fibronectin-rich extracellular matrix and displayed greater clonogenicity and differentiation potentialin vitro compared to ASC expanded only for 6 days (P0-ASC) or for 28 days with regular passaging (Pass-ASC). When implanted subcutaneously, Unpass-ASC produced bone tissue similarly to SVF cells, in contrast to P0- and Pass-ASC, which mainly formed fibrous tissue. Interestingly, clonogenic progenitors from native SVF and Unpass-ASC expressed low levels of the fibronectin receptorα 5 integrin (CD49e), which was instead upregulated in P0- and Pass-ASC. Mechanistically, induced activation of α5β1 integrin in Unpass-ASC led to a significant loss of bone formation in vivo. This study shows that ECM and regulation of α5β1-integrin signaling preserve ASC progenitor properties, including bone tissue-forming capacity, during in vitro expansion.
    [Show full text]
  • A Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 67), pp: 111405-111418 Research Paper A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells Mazin Gh. Al-Asadi1,2, Grace Brindle1, Marcos Castellanos3, Sean T. May3, Ken I. Mills4, Nigel H. Russell1,5, Claire H. Seedhouse1 and Monica Pallis5 1University of Nottingham, School of Medicine, Academic Haematology, Nottingham, UK 2University of Basrah, College of Medicine, Basrah, Iraq 3University of Nottingham, School of Biosciences, Nottingham, UK 4Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK 5Clinical Haematology, Nottingham University Hospitals, Nottingham, UK Correspondence to: Claire H. Seedhouse, email: [email protected] Keywords: AML; dormancy; gene expression profiling Received: September 19, 2017 Accepted: November 14, 2017 Published: November 30, 2017 Copyright: Al-Asadi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Dormant leukaemia initiating cells in the bone marrow niche are a crucial therapeutic target for total eradication of acute myeloid leukaemia. To study this cellular subset we created and validated an in vitro model employing the cell line TF- 1a, treated with Transforming Growth Factor β1 (TGFβ1) and a mammalian target of rapamycin inhibitor. The treated cells showed decreases in total RNA, Ki-67 and CD71, increased aldehyde dehydrogenase activity, forkhead box 03A (FOX03A) nuclear translocation and growth inhibition, with no evidence of apoptosis or differentiation. Using human genome gene expression profiling we identified a signature enriched for genes involved in adhesion, stemness/inhibition of differentiation and tumour suppression as well as canonical cell cycle regulation.
    [Show full text]
  • B-Cell Development, Activation, and Differentiation
    B-Cell Development, Activation, and Differentiation Sarah Holstein, MD, PhD Nov 13, 2014 Lymphoid tissues • Primary – Bone marrow – Thymus • Secondary – Lymph nodes – Spleen – Tonsils – Lymphoid tissue within GI and respiratory tracts Overview of B cell development • B cells are generated in the bone marrow • Takes 1-2 weeks to develop from hematopoietic stem cells to mature B cells • Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment • Immature B cell leaves the bone marrow and undergoes further differentiation • Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the same time eliminating self-reactive B cells Overview of B cell development • Early B cell development constitutes the steps that lead to B cell commitment and expression of surface immunoglobulin, production of mature B cells • Mature B cells leave the bone marrow and migrate to secondary lymphoid tissues • B cells then interact with exogenous antigen and/or T helper cells = antigen- dependent phase Overview of B cells Hematopoiesis • Hematopoietic stem cells (HSCs) source of all blood cells • Blood-forming cells first found in the yolk sac (primarily primitive rbc production) • HSCs arise in distal aorta ~3-4 weeks • HSCs migrate to the liver (primary site of hematopoiesis after 6 wks gestation) • Bone marrow hematopoiesis starts ~5 months of gestation Role of bone
    [Show full text]
  • Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-Cadherin/Β-Catenin) and Neoangiogenesis-Related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer
    ANTICANCER RESEARCH 36: 2271-2280 (2016) Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer ANTIGONY MITSELOU1, VASSILIKI GALANI2, URANIA SKOUFI3, DIMITRIS L. ARVANITIS4, EVANGELI LAMPRI5 and ELLI IOACHIM3 Departments of 1Forensic Pathology, 2Anatomy-Histology- Embryology and 5Pathology, Medical School, University of Ioannina, Ioannina, Greece; 3Department of Pathology, General Hospital “Hatzikostas”, Ioannina, Greece; 4Department of Anatomy-Histology-Embryology, Medical Faculty, University of Thessaly, Larissa, Greece Abstract. The Syndecan-1 protein plays a crucial role in syndecan-1, EMT markers, E-cadherin/β-catenin, in cell proliferation, cell adhesion, cell migration and association with endoglin (CD105), may be involved in angiogenesis and, at the same time, its co-expression with E- tumor progression and prognosis of CRC patients. Further cadherin is regulated during epithelial-mesenchymal studies are needed to clarify the interaction between these transition (EMT). In colorectal cancer (CRC), the expression proteins and tumor initiation and progression. of syndecan-1, E-cadherin/β-catenin complex is frequently disturbed. Angiogenesis is critical for the growth and Colorectal cancer (CRC) is the most common tumor of the metastatic spread of tumors. In the present study, we focused gastrointestinal system, the third most frequent cancer on the expression of these biological molecules and their worldwide and the fourth most frequent cause of death (1). prognostic significance in human CRC. Formalin-fixed In Greece, the last two decades, CRC has a high incidence paraffin-embedded surgical specimens from 69 patients with and mortality rates, in both sexes (2). CRC frequency varies CRC were immunostained for syndecan-1, E-cadherin, β- markedly by region and community.
    [Show full text]
  • 6191.Full-Text.Pdf
    Macrophage-Inflammatory Protein-1α Receptor Expression on Normal and Chronic Myeloid Leukemia CD34+ Cells This information is current as Sian E. Nicholls, Guy Lucas, Gerard J. Graham, Nigel H. of September 26, 2021. Russell, Rachel Mottram, Anthony D. Whetton and Anne-Marie Buckle J Immunol 1999; 162:6191-6199; ; http://www.jimmunol.org/content/162/10/6191 Downloaded from References This article cites 41 articles, 27 of which you can access for free at: http://www.jimmunol.org/content/162/10/6191.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Macrophage-Inflammatory Protein-1a Receptor Expression on Normal and Chronic Myeloid Leukemia CD341 Cells1 Sian E. Nicholls,* Guy Lucas,† Gerard J. Graham,‡ Nigel H. Russell,§ Rachel Mottram,* Anthony D. Whetton,* and Anne-Marie Buckle2* We have assessed expression of MIP-1a binding sites on the surface of CD341 cells from normal bone marrow (NBM) and chronic myeloid leukemia (CML) peripheral blood.
    [Show full text]